The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00044148

Enrollment

Unknown

Registered

2002-08-21

Start date

2002-07-16

Completion date

2004-04-28

Last updated

2017-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Keywords

Persistent Albuminuria

Brief summary

The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.

Interventions

DRUGLY333531

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Type 2 diabetes mellitus * Greater than or equal to 30 years of age * Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.

Exclusion criteria

* Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females * B/P greater than 150 systolic and greater than 90 diastolic * Hemoglobin Alc greater than 11% * Liver Function Tests 2 times upper limit of normal * Poor medical or psychiatric risk.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026